Hindman Andrew A. 4
4 · Theravance Biopharma, Inc. · Filed Nov 22, 2022
Insider Transaction Report
Form 4
Hindman Andrew A.
SVP, Chief Financial Officer
Transactions
- Sale
Ordinary Shares
2022-11-18$11.02/sh−65,000$716,242→ 409,771 total - Tax Payment
Ordinary Shares
2022-11-20$10.85/sh−25,057$271,868→ 384,714 total
Footnotes (3)
- [F1]This transaction was executed in multiple trades at prices from $10.7891 to $11.2750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F2]Includes 1,264 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2022.
- [F3]Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.